IFRX InflaRx N.V.
InflaRx N.V. (IFRX) is expected to report earnings on February 2, 2027, before the market open. The consensus earnings estimate is a loss of $0.05 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -33.5% since its last earnings release on November 3, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About InflaRx N.V.
InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a.
Sector
Healthcare
Industry
Biotechnology
Charts powered in part by Lightweight Charts™ by TradingView.